Aptevo Therapeutics

On March 26, 2026, Aptevo Therapeutics released figures for the most recent quarter and reported a loss of $75.85 per share. Earnings per share for the full year were -$87.27. By comparison, unusually large negative values of -$29,653.20 and -$31,456.80 per share were reported in the prior-year quarter and year, respectively. » More on finanzen.net

Aptevo Therapeutics has closed a $60 million equity financing facility with Yorkville Advisors Global, providing incremental access to capital on market-based terms. The agreement, together with the company’s existing cash balance, is expected to fund operations through 2029 and support ongoing clinical development and preclinical programs. The stock rose 10.4% in pre-market trading. Aptevo says funds are available flexibly; focus includes the bispecific candidate Mipletamig in a phase 1b/2 study in AML. » More on de.investing.com

Aptevo Therapeutics effected a 1-for-18 reverse stock split on December 29, 2025 at 5:01 p.m. ET, combining each 18 existing common shares into one share. The number of outstanding shares will be reduced from roughly 18 million to about 1 million, the par value remains unchanged, and exercise prices and share counts of options and RSUs will be adjusted proportionally. No fractional shares will be issued — affected shareholders will receive cash payments, warrant holders will be rounded up to the next whole share — and the shares will trade on Nasdaq as split-adjusted from the trading day with the new CUSIP 03835L702. » More on de.investing.com